A new rapid home test for faecal calprotectin in ulcerative colitis

Alimentary Pharmacology and Therapeutics

Volumn 31, Issue 2, 2010, Pages 323-330

  Elkjaer, M ^a   Burisch, J ^a   Voxen Hansen, V ^a   Deibjerg Kristensen, B ^a   Slott Jensen, J K ^b   Munkholm, P ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b Slott Stat   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN;

ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES; GOLD STANDARD; INTERNET; KAPPA STATISTICS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SELF CARE; SENSITIVITY AND SPECIFICITY; ULCERATIVE COLITIS;

COLITIS, ULCERATIVE; CONFIDENCE INTERVALS; DIAGNOSTIC TESTS, ROUTINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY;

EID: 72949086178     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.04164.x     Document Type: Article

References (22)

1. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004 99 : 1371 1385.
2. Elkjaer M, Burisch J, Avnstrom S, Lynge E, Munkholm P. Development of a Web-based concept for patients with ulcerative colitis and 5-aminosalicylic acid treatment. Eur J Gastroenterol Hepatol 2009 21 : 2326 2331.
3. Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis 2006 12 : 524 534.
4. Ansari R, Attari F, Razjouyan H, et al. Ulcerative colitis and irritable bowel syndrome: relationships with quality of life. Eur J Gastroenterol Hepatol 2008 20 : 46 50.
5. Walkiewicz D, Werlin SL, Fish D, Scanlon M, Hanaway P, Kugathasan S. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2008 14 : 669 673.
6. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000 119 : 15 22.
7. Roseth AG, Aadland E, Jahnsen J, Raknerud N. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997 58 : 176 180.
8. Bunn SK, Bisset WM, Main MJ, Gray ES, Olson S, Golden BE. Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001 33 : 14 22.
9. Kallel L, Ayadi I, Matri S, et al. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study. Eur J Gastroenterol Hepatol 2009 [in press].
10. D'Inca R, Dal PE, Di L V, et al. Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol 2008 103 : 2007 2014.
11. Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 2005 54 : 364 368.
12. Fagerhol MK, Dale I, Anderson I. Release and quantitation of a leukocyte derived protein (L1). Scand J Gastroenterol 1980 24 : 393 398.
13. Roseth AG, Fagerhol MK, Aadland E, Schjonsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992 27 : 793 798.
14. Steinbakk M, Naess-Andresen CF, Lingaas E, Dale I, Brandtzaeg P, Fagerhol MK. Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet 1990 336 : 763 765.
15. Yui S, Mikami M, Tsurumaki K, Yamazaki M. Growth-inhibitory and apoptosis-inducing activities of calprotectin derived from inflammatory exudate cells on normal fibroblasts: regulation by metal ions. J Leukoc Biol 1997 61 : 50 7.
16. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986 1 : 307 310.
17. Altman DG. Practical Statistics for Medical Research, 1st ed., Chapman & Hall, London. 1991, S. 410 414.
18. Sipponen T, Savilahti E, Karkkainen P, et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis 2008 14 : 1392 1398.
19. Vestergaard TA, Nielsen SL, Dahlerup JF, Hornung N. Fecal calprotectin: assessment of a rapid test. Scand J Clin Lab Invest 2008 68 : 343 347.
20. Otten CM, Kok L, Witteman BJ, et al. Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome. Clin Chem Lab Med 2008 46 : 1275 1280.
21. Damms A, Bischoff SC. Validation and clinical significance of a new calprotectin rapid test for the diagnosis of gastrointestinal diseases. Int J Colorectal Dis 2008 23 : 985 992.
22. Elkjaer M, Moser G, Reinisch W, et al. IBD patients need in health quality of care ECCO consensus. Journal of Crohn's and Colitis 2008 2 : 181 188.